RESUMEN
A simple, rapid, sensitive and specific LC-MS/MS method was developed and validated for the quantitative determination of doxylamine in human plasma, using isotope doxylamine-d5 as internal standard (IS). The detection was conducted on a QTRAP 5500 tandem mass spectrometer coupled with electrospray ionization (ESI) source in positive ion mode. Quantification was achieved by positive electrospray ionization containing multiple reaction monitoring (MRM) transitions of m/z 271.0â182.0 for doxylamine and m/z 276.2â187.3 for IS. The mobile phase A was methanol, and mobile phase B was 20 mM ammonium acetate (0.2 % formic acid) in water, using a gradient elution procedure at a flow rate of 0.6 mL/min. The method was validated with a sensitivity of 0.500 ng/mL and a linear concentration range of 0.500-200 ng/mL. The inter-batch precision (%CV) was less than 5.4 %, and the accuracy deviation (%RE) ranged from - 10.6 % to 3.7 %; the inter-batch precision (%CV) was less than 6.6 %, and the accuracy deviation (%RE) was ranged from - 2.7 % to 0.1 %. The selectivity, sensitivity, extraction recovery, matrix effect, carryover, dilution reliability, stability and other characteristics were within the acceptable range. This validated method was successfully applied to a bioequivalence study that orally administered 25 mg of doxylamine succinate tablets in 60 healthy Chinese volunteers.
Asunto(s)
Doxilamina/sangre , Doxilamina/farmacocinética , Antagonistas de los Receptores Histamínicos H1/sangre , Antagonistas de los Receptores Histamínicos H1/farmacocinética , Espectrometría de Masas en Tándem/métodos , Administración Oral , China , Cromatografía Liquida/métodos , Doxilamina/administración & dosificación , Voluntarios Sanos , Antagonistas de los Receptores Histamínicos H1/administración & dosificación , Humanos , Metanol , Reproducibilidad de los Resultados , Espectrometría de Masa por Ionización de Electrospray , Comprimidos , Equivalencia TerapéuticaRESUMEN
OBJECTIVES: The aim of this experiment was mainly to examine the effects of intrathecally injected doxylamine and triprolidine, two antihistamine drugs spinal motor and sensory functions. METHODS: After intrathecally injecting the rats with five different doses, the dose-response curves of spinal sensory and motor block with doxylamine and triprolidine were constructed. In comparison with the local anaesthetic mepivacaine, the quality and duration of spinal anaesthesia with doxylamine or triprolidine were conducted. KEY FINDINGS: Doxylamine, mepivacaine and triprolidine elicited spinal motor and sensory (nociception and proprioception) blockades in a dose-dependent fashion. On the ED50 (50% effective dose) basis, the rank order of drug potency was triprolidine > mepivacaine > doxylamine (P < 0.05) at provoking spinal motor, proprioceptive and nociceptive blockades. On the equianaesthetic doses (ED25 , ED50 and ED75 ), the duration of spinal anaesthesia with doxylamine was longer (P < 0.01) than that with mepivacaine or triprolidine. Moreover, doxylamine or triprolidine displayed greater potency (ED50 ) (P < 0.05) and duration (P < 0.05) of sensory block over motor block. CONCLUSIONS: Doxylamine or triprolidine produces a dose-dependent effect of spinal motor and sensory block. Triprolidine with a better nociception-selective action over motor block has a better potency than mepivacaine or doxylamine. Doxylamine and triprolidine produce longer durations than mepivacaine.
Asunto(s)
Doxilamina/farmacología , Antagonistas de los Receptores Histamínicos/farmacología , Bloqueo Nervioso/métodos , Triprolidina/farmacología , Anestésicos Locales/farmacología , Animales , Relación Dosis-Respuesta a Droga , Doxilamina/administración & dosificación , Antagonistas de los Receptores Histamínicos/administración & dosificación , Inyecciones Espinales , Masculino , Mepivacaína/farmacología , Actividad Motora/efectos de los fármacos , Movimiento/efectos de los fármacos , Nocicepción/efectos de los fármacos , Propiocepción/efectos de los fármacos , Ratas , Ratas Sprague-Dawley , Triprolidina/administración & dosificaciónRESUMEN
Spray-dried chitosan microparticles have been widely exploited as vehicles for mucosal drug delivery. Despite their advantages as pharmaceutical formulations, one of the major challenges is achieving sustained drug release, which would diminish toxicity and dosage frequency. The aim of this study was to formulate mucoadhesive glutaraldehyde cross-linked chitosan microparticles loaded with doxylamine succinate and pyridoxine hydrochloride as potential nasal drug delivery systems with sustained release. Microparticle models were formulated via spray-drying technique, using glutaraldehyde in different concentrations (0.1-1.0â¯mg/mL) as a cross-linking agent for chitosan. The obtained particles were with spherical shape, smooth surface and median diameter of 4⯵m. The drug entrapment efficiency was high (80.47%-94.25%), indicating a tendency to decrease at higher glutaraldehyde concentrations. FTIR data demonstrated that there were no chemical interactions between glutaraldehyde and the drugs. The in vitro studies showed that the cross-linking process substantially limited particles swelling. The cross-linked particles exhibited sustained drug release characteristics at pHâ¯6.8 over a period of 5â¯h with an initial burst-effect in the first 30â¯min. Drug release followed Korsmeyer-Peppas kinetics. Although a decrease of the particles mucoadhesive properties was observed after modification, all cross-linked formulations demonstrated high in vitro adsorption of mucin. The proposed models of mucoadhesive microsphere with sustained drug release are a perspective ground for further development of a novel delivery system for nasal administration of doxylamine and pyridoxine.
Asunto(s)
Antieméticos/química , Química Farmacéutica/métodos , Quitosano/química , Reactivos de Enlaces Cruzados/química , Diciclomina/química , Doxilamina/química , Portadores de Fármacos , Glutaral/química , Piridoxina/química , Adhesividad , Administración Intranasal , Antieméticos/administración & dosificación , Preparaciones de Acción Retardada , Diciclomina/administración & dosificación , Doxilamina/administración & dosificación , Combinación de Medicamentos , Composición de Medicamentos , Liberación de Fármacos , Estudios de Factibilidad , Mucinas Gástricas/química , Cinética , Microesferas , Piridoxina/administración & dosificación , SolubilidadRESUMEN
BACKGROUND: We aimed to evaluate the effect of doxylamine, a first generation antihistamine, as a local analgesic agent by comparing its effect to bupivacaine. METHODS: After blocking the cutaneous trunci muscle reflex (CTMR) by subcutaneous injection of doxylamine, we assessed doxylamine's cutaneous analgesic effect in rats. The dose-related effect and duration of doxylamine on infiltrative cutaneous analgesia were compared with that of bupivacaine. RESULTS: We demonstrated that doxylamine, as well as the local anesthetic bupivacaine produced the cutaneous analgesic effects in a dose-related fashion. At the equipotent dose (50% effective doses (ED50)), the relative potency was bupivacaine (0.41 (0.36-0.48) mmol)> doxylamine (7.39 (6.91-7.91)mmol) (p<0.01). On an equipotent basis (ED25, ED50 and ED75), subcutaneous doxylamine resulted in greater duration of action (p<0.01) than bupivacaine at producing cutaneous analgesia. CONCLUSIONS: The result of this experiment indicated that doxylamine has the local anesthetic property less potent than bupivacaine, but its nociceptive block duration is longer than that of bupivacaine at an equianalgesic dose.
Asunto(s)
Anestésicos Locales/administración & dosificación , Doxilamina/administración & dosificación , Administración Cutánea , Analgesia/métodos , Animales , Bupivacaína/administración & dosificación , Relación Dosis-Respuesta a Droga , Inyecciones Subcutáneas/métodos , Masculino , Dolor/tratamiento farmacológico , Ratas , Ratas Sprague-Dawley , Piel/metabolismoRESUMEN
BACKGROUND: Doxylamine-pyridoxine is recommended as a first line treatment for nausea and vomiting during pregnancy and it is commonly prescribed. We re-analysed the findings of a previously reported superiority trial of doxylamine-pyridoxine for the treatment of nausea and vomiting during pregnancy using the clinical study report obtained from Health Canada. METHODS AND FINDINGS: We re-analysed individual level data for a parallel arm randomized controlled trial that was conducted in six outpatient obstetrical practices in the United States. Pregnant women between 7 and 14 weeks of gestation with moderate nausea and vomiting of pregnancy symptoms. The active treatment was a tablet containing both doxylamine 10 mg and pyridoxine 10 mg taken between 2 and 4 times per day for 14 days depending on symptoms. The control was an identical placebo tablet taken using the same instructions. The primary outcome measure was improvement in nausea and vomiting of symptoms scores using the 13-point pregnancy unique quantification of emesis scale between baseline and 14 days using an ANCOVA. 140 participants were randomized into each group. Data for 131 active treatment participants and 125 control participants were analysed. On the final day of the trial, 101 active treatment participants and 86 control participants provided primary outcome measures. There was greater improvement in symptoms scores with doxylamine-pyridoxine compared with placebo (0.73 points; 95% CI 0.21 to 1.25) when last observation carried forward imputation was used for missing data but the difference is not statistically significant using other approaches to missing data (e.g. 0.38; 95% CI -0.08 to 0.84 using complete data). CONCLUSIONS: There is a trend towards efficacy for nausea and vomiting symptoms with doxylamine-pyridoxine compared with placebo but the statistical significance of the difference depends on the method of handling missing data and the magnitude of the difference suggests that there is no clinically important benefit employing the prespecified minimal clinically important difference or "expected difference" of 3 points. TRIAL REGISTRATION: Clinical Trial NCT00614445.
Asunto(s)
Doxilamina/administración & dosificación , Náuseas Matinales/prevención & control , Piridoxina/administración & dosificación , Quimioterapia Combinada , Femenino , Humanos , Placebos , EmbarazoRESUMEN
BACKGROUND: Nausea and vomiting of pregnancy (NVP) affects up to 80% of expecting mothers. In April 2013 the FDA approved the delayed-release combination of doxylamine succinate and pyridoxine hydrochloride (Diclegis®) for NVP, based in part, on the results of a phase III randomized trial demonstrating the efficacy of this drug combination [study drug marketed under the trade name Diclectin® in Canada and Diclegis® in the United States] compared to placebo in pregnant women. Study drug dosing occurred for 14 days, which is substantially longer than what has been performed in similar studies. The objective of this study was to evaluate, through secondary analysis, whether the primary measure of efficacy can be demonstrated after five days of treatment. METHODS: Women suffering from NVP were randomized to receive Diclegis® (n = 131) or placebo (n = 125) for 14 days at doses ranging from two to four tablets a day, based on a pre-specified titration protocol. The primary efficacy endpoint was the change in the validated Pregnancy-Unique Quantification of Emesis (PUQE) score at baseline versus Day 15 between Diclegis®-treated and placebo-treated women. For the present study, the change in PUQE score between baseline and Day 15 (end of the study) was compared to the changes observed for Days 3, 4, and 5. RESULTS: The use of delayed-release doxylamine succinate and pyridoxine hydrochloride tablets show improved NVP symptom control as compared to placebo on Days 3,4 and 5, with sustained efficacy until the end of the trial. CONCLUSION: A four day study drug dosing trial with Diclegis® is sufficient to document efficacy, as the results are similar to those achieved after 14 study drug dosing days. The benefit seen at the earlier time validates drug efficacy and minimizes the natural course of improvement. TRIAL REGISTRATION: CTR No. NCT006 14445 2007.
Asunto(s)
Antieméticos/uso terapéutico , Diciclomina/uso terapéutico , Doxilamina/uso terapéutico , Náuseas Matinales/tratamiento farmacológico , Piridoxina/uso terapéutico , Antieméticos/administración & dosificación , Preparaciones de Acción Retardada , Diciclomina/administración & dosificación , Doxilamina/administración & dosificación , Combinación de Medicamentos , Femenino , Humanos , Embarazo , Piridoxina/administración & dosificación , Factores de TiempoAsunto(s)
Diciclomina/uso terapéutico , Doxilamina/uso terapéutico , Náuseas Matinales/tratamiento farmacológico , Piridoxina/uso terapéutico , Preparaciones de Acción Retardada , Diciclomina/administración & dosificación , Doxilamina/administración & dosificación , Combinación de Medicamentos , Femenino , Humanos , Embarazo , Piridoxina/administración & dosificaciónRESUMEN
BACKGROUND: Nausea and vomiting of pregnancy (NVP) is the most common medical condition in pregnancy, affecting up to 80% of expecting mothers. In April 2013 the FDA approved the delayed release combination of doxylamine succinate and -pyridoxine hydrochloride (Diclegis®) for NVP, following a phase 3 randomized trial in pregnant women. The fetal safety of this medication has been proven by numerous studies. However, because it is the only FDA-approved medication for NVP that is likely to be used by a large number of pregnant women, its maternal safety is an important public health question. The Objective is to evaluate the maternal safety of doxylamine succinate -pyridoxine hydrochloride delayed-release preparation (Diclegis® as compared to placebo. METHODS: We randomized women suffering from NVP to receive Diclegis® (n = 131) or placebo (n = 125) for 14 days at doses ranging from 2-4 tablets a day, based on a pre-specified titration protocol response to symptoms. Adverse events were collected through patient diaries, clinical examination and laboratory testing. RESULTS: Doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg use was not associated with an increased rate of any adverse event over placebo, including CNS depression, gastrointestinal or cardiovascular involvement. CONCLUSIONS: Doxylamine succinate-pyridoxine hydrochloride delayed release combination is safe and well tolerated by pregnant women when used in the recommended dose of up to 4 tablets daily in treating nausea and vomiting of pregnancy. TRIAL REGISTRATION: Clinical Trial Registration No: NCT00614445 .
Asunto(s)
Diciclomina , Doxilamina , Náusea , Complicaciones del Embarazo/tratamiento farmacológico , Piridoxina , Vómitos , Adulto , Antieméticos/administración & dosificación , Antieméticos/efectos adversos , Preparaciones de Acción Retardada/administración & dosificación , Preparaciones de Acción Retardada/efectos adversos , Diciclomina/administración & dosificación , Diciclomina/efectos adversos , Método Doble Ciego , Doxilamina/administración & dosificación , Doxilamina/efectos adversos , Combinación de Medicamentos , Monitoreo de Drogas/métodos , Femenino , Antagonistas de los Receptores Histamínicos H1/administración & dosificación , Antagonistas de los Receptores Histamínicos H1/efectos adversos , Humanos , Náusea/tratamiento farmacológico , Náusea/etiología , Embarazo , Piridoxina/administración & dosificación , Piridoxina/efectos adversos , Resultado del Tratamiento , Complejo Vitamínico B , Vómitos/tratamiento farmacológico , Vómitos/etiologíaRESUMEN
OBJECTIVE: To evaluate whether ondansetron or the combination of doxylamine and pyridoxine was superior for the treatment of nausea and vomiting of pregnancy. METHODS: This was a double-blind, randomized, controlled trial in which women with nausea and vomiting of pregnancy were assigned to 4 mg of ondansetron plus a placebo tablet or 25 mg pyridoxine plus 12.5 mg of doxylamine for 5 days. The primary outcome was an improvement in nausea as reported on a 100-mm visual analog scale (VAS). Secondary outcomes were a reduction in vomiting on the VAS and the proportion of patients reporting sedation or constipation while using either study regimen. RESULTS: Thirty-six women (18 in each group) were randomized to either ondansetron or pyridoxine and doxylamine, of whom 13 (72%) and 17 (94%) completed follow-up, respectively. There were no differences among the groups with regard to demographic characteristics or baseline nausea. Patients randomized to ondansetron were more likely to have an improvement in their baseline nausea as compared with those using pyridoxine and doxylamine over the course of 5 days of treatment (median VAS score decreased 51 mm [interquartile range 37-64] compared with 20 mm [8-51]; P=.019). Furthermore, women using ondansetron reported less vomiting (median VAS decreased 41 [interquartile range 17-57] compared with 17 [-4 to 38]; P=.049). There was no significant difference between the groups regarding sedation or constipation. CONCLUSION: Our investigation showed ondansetron to be superior to the combination of pyridoxine and doxylamine in the treatment of nausea and emesis in pregnancy. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, www.clinicaltrials.gov, NCT01668069. LEVEL OF EVIDENCE: : I.
Asunto(s)
Doxilamina/administración & dosificación , Náuseas Matinales/diagnóstico , Náuseas Matinales/tratamiento farmacológico , Ondansetrón/administración & dosificación , Piridoxina/administración & dosificación , Adulto , Antieméticos/administración & dosificación , Método Doble Ciego , Quimioterapia Combinada , Femenino , Estudios de Seguimiento , Humanos , Hiperemesis Gravídica/tratamiento farmacológico , Hiperemesis Gravídica/fisiopatología , Náusea/tratamiento farmacológico , Náusea/fisiopatología , Satisfacción del Paciente/estadística & datos numéricos , Embarazo , Medición de Riesgo , Índice de Severidad de la Enfermedad , Resultado del Tratamiento , Vómitos/tratamiento farmacológico , Vómitos/fisiopatología , Adulto JovenRESUMEN
Nausea and vomiting of pregnancy (NVP) affects up to 80 percent of pregnant women. This condition is usually self-limiting, but the symptoms can be distressing and interfere with work, social activities and sleep. Symptoms can often be managed by diet and lifestyle changes, but these interventions may not be successful for everyone. In April 2013, the U.S. Food and Drug Administration approved doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg (Diclegis) as the first medication to specifically treat NVP in more than 30 years. This article reviews the indications, dosage and nursing interventions associated with using doxylamine succinate/pyridoxine to treat NVP.
Asunto(s)
Antieméticos/uso terapéutico , Diciclomina/uso terapéutico , Doxilamina/uso terapéutico , Hiperemesis Gravídica/tratamiento farmacológico , Náuseas Matinales/tratamiento farmacológico , Piridoxina/uso terapéutico , Anomalías Inducidas por Medicamentos/prevención & control , Antieméticos/administración & dosificación , Antieméticos/efectos adversos , Preparaciones de Acción Retardada , Diciclomina/administración & dosificación , Diciclomina/efectos adversos , Doxilamina/administración & dosificación , Doxilamina/efectos adversos , Esquema de Medicación , Combinación de Medicamentos , Servicios de Información sobre Medicamentos , Femenino , Humanos , Hiperemesis Gravídica/etiología , Náuseas Matinales/etiología , Enfermería Obstétrica/normas , Embarazo , Piridoxina/administración & dosificación , Piridoxina/efectos adversos , Equivalencia TerapéuticaRESUMEN
A young woman's death at home was attributed to new onset diabetic ketoacidosis with subsequent litigation supported by several expert consultants, despite a history and postmortem findings inconsistent with this diagnosis. More thorough tissue study of the heart and analysis of the circumstances led to a credible explanation of the entire scenario.
Asunto(s)
Muerte Súbita/etiología , Cetoacidosis Diabética/diagnóstico , Acetaminofén/administración & dosificación , Acetaminofén/efectos adversos , Acetona/sangre , Adolescente , Causas de Muerte , Dextrometorfano/administración & dosificación , Dextrometorfano/efectos adversos , Diabetes Mellitus/diagnóstico , Errores Diagnósticos , Doxilamina/administración & dosificación , Doxilamina/efectos adversos , Combinación de Medicamentos , Células Epiteliales/patología , Etanol/sangre , Femenino , Glucosa/análisis , Glucogenólisis , Humanos , Cetonas/análisis , Túbulos Renales/patología , Hígado/citología , Mala Praxis , Seudoefedrina/administración & dosificación , Seudoefedrina/efectos adversos , Cuerpo Vítreo/química , Pérdida de PesoAsunto(s)
Antieméticos/uso terapéutico , Doxilamina/uso terapéutico , Náusea/tratamiento farmacológico , Complicaciones del Embarazo/tratamiento farmacológico , Piridoxina/uso terapéutico , Vómitos/tratamiento farmacológico , Antieméticos/administración & dosificación , Preparaciones de Acción Retardada , Diciclomina , Doxilamina/administración & dosificación , Combinación de Medicamentos , Femenino , Humanos , Embarazo , Piridoxina/administración & dosificaciónRESUMEN
To characterize doxylamine pharmacokinetics in children. This study was conducted in 41 subjects, ages 2-17 years. Doxylamine succinate doses based on age/weight ranged from 3.125 to 12.5 mg. A single oral dose was administered with 2 to 4 oz. of water or decaffeinated beverages â¼2 hours after a light breakfast. Plasma samples were obtained before and for 72 hours after dosing and analyzed for doxylamine using HPLC MS/MS. Pharmacokinetic parameters were estimated using non-compartmental methods and relationships with age were assessed using linear regression. Over the fourfold dose range, Cmax was similar while AUC increased only 60%, although not statistically significant (P-value = 0.0517). As expected due to increasing body size, CLo and Vz /F increased with age. Due to a similar increase with age for Clo and Vz /F, no age-related differences in t1/2,z were observed (â¼16 hours). Allometric scaling indicated no maturation related changes in CLo ; although Vz /F remained age-dependent, the predicted range decreased â¼70%. Overall, the single doses were well tolerated. Somnolence was the most common reported AE with no apparent differences in incidence noted with age. An age/weight dosing nomogram utilizing a fourfold range of doses achieves similar Cmax , whereas AUC increases only 60%.
Asunto(s)
Doxilamina/análogos & derivados , Antagonistas de los Receptores Histamínicos H1/administración & dosificación , Antagonistas de los Receptores Histamínicos H1/farmacocinética , Administración Oral , Adolescente , Área Bajo la Curva , Niño , Preescolar , Relación Dosis-Respuesta a Droga , Doxilamina/administración & dosificación , Doxilamina/sangre , Doxilamina/farmacocinética , Femenino , Antagonistas de los Receptores Histamínicos H1/sangre , Humanos , MasculinoRESUMEN
BACKGROUND: Doxylamine succinate, an ethanolamine-based antihistamine, is used in the short-term management of insomnia because of its sedative effects. No data on the dose proportionality of the pharmacokinetics of doxylamine are available, although this drug has been marketed in European countries for more than 50 years. OBJECTIVE: The objective of this study was to evaluate and compare the dose proportionality between two marketed strengths (12.5 mg and 25 mg) of doxylamine hydrogen succinate after a single oral dose administration under fasting conditions in healthy human subjects. STUDY DESIGN: This was a single-center, randomized, single dose, laboratory-blinded, two-period, two-sequence, crossover study. SETTING: The study was conducted in a phase I clinical unit. SUBJECTS AND METHODS: A single oral dose of doxylamine hydrogen succinate of 12.5 mg (equivalent to 8.7 mg of doxylamine base) or 25 mg (equivalent to 17.4 mg of doxylamine base) was administered to healthy volunteers under fasting conditions in each study period. The drug administrations were separated by a wash-out period of 7 calendar days. Blood samples were collected for up to 60 h post-dose, and plasma doxylamine levels were determined by an ultra high-performance liquid chromatography method with tandem mass spectrometry detection. Pharmacokinetic parameters were calculated using non-compartmental analysis. Dose proportionality was assessed based on the parameter area under the concentration-time curve (AUCt normalized). Safety was evaluated through assessment of adverse events, standard laboratory evaluations, vital signs and 12-lead electrocardiogram (ECG). RESULTS: In total, 12 healthy volunteers (3 male; 9 female) were included in the study. Mean maximum observed plasma concentration (Cmax) and area under the concentration-time curve from time zero to time t (AUCt ) of doxylamine hydrogen succinate 12.5 mg and 25 mg tablets increased linearly and dose-dependently [12.5 mg: mean Cmax 61.94 ng/mL, coefficient of variation (CV) 23.2%; mean AUCt 817.33 ng·h/mL, CV 27.4%; and 25 mg: mean Cmax 124.91 ng/mL, CV 18.7%; mean AUCt 1630.85 ng·h/mL, CV 22.8%]. Mean AUCt normalized was 815.43 ng·h/mL, CV 22.8% for 25 mg. The dose-normalized geometric mean ratio (%, 12.5 mg/25 mg) of AUCt was 98.92 (90% CI: 92.46, 105.83). The most common adverse event was somnolence. CONCLUSIONS: Exposure to doxylamine was proportional over the therapeutic dose range of 12.5-25 mg in healthy volunteers. Based on the results, a predictable and linear increase in systemic exposure can be expected. Doxylamine hydrogen succinate was safe and well tolerated.
Asunto(s)
Doxilamina/análogos & derivados , Antagonistas de los Receptores Histamínicos H1/farmacocinética , Adulto , Disponibilidad Biológica , Estudios Cruzados , Relación Dosis-Respuesta a Droga , Doxilamina/administración & dosificación , Doxilamina/efectos adversos , Doxilamina/sangre , Doxilamina/farmacocinética , Ayuno/sangre , Femenino , Voluntarios Sanos , Antagonistas de los Receptores Histamínicos H1/efectos adversos , Antagonistas de los Receptores Histamínicos H1/sangre , Humanos , Masculino , Cumplimiento de la Medicación , Persona de Mediana Edad , ComprimidosRESUMEN
BACKGROUND: Diclectin (pyridoxine 10 mg and doxylamine 10 mg) has traditionally been used to treat nausea and vomiting of pregnancy (NVP); however, this drug is unavailable in many countries. OBJECTIVES: To evaluate the efficacy and safety of a simple bi-daily treatment regimen with the combination of pyridoxine (50 mg twice daily) and doxylamine (25-50 mg) as an alternative treatment for NVP. METHODS: A prospective case-controlled observational study of mother-infant pairs was conducted between February 2008 and December 2010. All women who contacted the Beilinson Teratology Information Service (BELTIS) regarding treatment of NVP were eligible for inclusion. Using data on NVP severity, treatment efficacy and outcomes, we compared the two groups of women: those treated with the combination of pyridoxine and doxylamine (treatment group, n=29) and those treated with metoclopramide (control group, n=29). RESULTS: Moderate to severe symptoms were present in 97% of the treatment group women vs. 69% of control group women (P < 0.01). Despite increased symptom severity in the treatment group, the combination regimen was efficacious: 20/29 (69%) vs. 18/25 (72%) in the treatment vs. control women respectively (P = 0.65). There were no congenital anomalies in the treatment group. Follow-up was normal for all infants. CONCLUSIONS: Bi-daily combination therapy with pyridoxine and doxylamine for NVP is safe, has comparable efficacy to metoclopramide, and is a treatment alternative in countries where Diclectin is not available. Despite symptoms warranting counseling by a teratology information service, more than a third of women do not take the suggested treatment.
Asunto(s)
Doxilamina/administración & dosificación , Náusea/tratamiento farmacológico , Complicaciones del Embarazo/tratamiento farmacológico , Piridoxina/administración & dosificación , Vómitos/tratamiento farmacológico , Administración Oral , Adulto , Antieméticos/administración & dosificación , Estudios de Casos y Controles , Diciclomina , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Combinación de Medicamentos , Femenino , Humanos , Embarazo , Estudios Prospectivos , Encuestas y Cuestionarios , Resultado del Tratamiento , Complejo Vitamínico B/administración & dosificaciónRESUMEN
Although Diclectin (doxylamine/pyridoxine delayed-released combination) is widely used in Canada, its pharmacokinetics (PK) during pregnancy has never been described. The objective of this study was to compare the PK of doxylamine/pyridoxine delayed-released combination in pregnant versus nonpregnant women. The apparent clearances (CL) of doxylamine and pyridoxal 5'-phosphate (PLP; the active metabolite of vitamin B(6) ) during the first-trimester pregnancy in women who participated in a Diclectin randomized trial were compared with those of healthy, adult, nonpregnant women who participated in a voluntary PK trial. Eighteen nonpregnant women were compared with 50 pregnant women who were treated with Diclectin. There was no difference in the apparent CL of doxylamine in women in their first trimester of pregnancy when compared with nonpregnant women on day 4 (median = 196.7 vs 249.5 mL/h/kg, respectively, P = .065), day 8 (median = 248.4 vs 249.5 mL/h/kg, respectively, P = .82), and day 15 (median = 200.9 vs 249.5 mL/h/kg, respectively, P = .55). No difference was found in the apparent CL of PLP on day 15 (median = 342.3 vs 314.7 mL/h/kg, respectively, P = .92). There was no pregnancy-induced effect in the apparent CL of either doxylamine or PLP in women during the first trimester of pregnancy despite the existence of morning sickness.
Asunto(s)
Antieméticos/farmacocinética , Doxilamina/farmacocinética , Embarazo/metabolismo , Piridoxina/farmacocinética , Adolescente , Adulto , Antieméticos/administración & dosificación , Antieméticos/sangre , Preparaciones de Acción Retardada/administración & dosificación , Preparaciones de Acción Retardada/farmacocinética , Diciclomina , Método Doble Ciego , Doxilamina/administración & dosificación , Doxilamina/sangre , Combinación de Medicamentos , Femenino , Humanos , Persona de Mediana Edad , Primer Trimestre del Embarazo/metabolismo , Piridoxina/administración & dosificación , Piridoxina/sangre , Adulto JovenRESUMEN
BACKGROUND: Doxylamine succinate, an ethanolamine-based antihistamine, is used in the short-term management of insomnia because of its sedative effects. The data available on the pharmacokinetic profile of doxylamine in humans are limited, notwithstanding that this drug has been marketed in European countries for more than 50 years. In fact, no data on the effect of food on the pharmacokinetic parameters of doxylamine are available. OBJECTIVE: The objective of this study was to evaluate the pharmacokinetic parameters of doxylamine following a single oral dose of doxylamine hydrogen succinate 25 mg in healthy human subjects under fed and fasting conditions. STUDY DESIGN: This was a single-center, randomized, single-dose, laboratory-blinded, two-period, two-sequence, crossover study. SETTING: The study was conducted in a phase I clinical unit. SUBJECTS AND METHODS: A single oral dose of doxylamine hydrogen succinate 25 mg (equivalent to 17.4 mg of doxylamine base) was administered to healthy volunteers under either fed conditions (high-fat, high-calorie food intake) or fasting conditions in each study period. The drug administrations were separated by a wash-out period of seven calendar days. Plasma samples were collected for up to 60 hours postdose, and plasma doxylamine concentrations were determined by a high-performance liquid chromatography method with tandem mass spectrometry detection. Pharmacokinetic parameters were calculated using noncompartmental analysis. Safety was evaluated through assessment of adverse events, standard laboratory evaluations, vital signs, and 12-lead electrocardiography. RESULTS: In total, 24 healthy subjects (12 male and 12 female) were included in the study. Doxylamine succinate 25 mg tablets exhibited similar oral bioavailability of doxylamine in the fasting state (mean maximum plasma drug concentration [C(max)] 118.21 ng/mL, coefficient of variation [CV] 19.2%; mean area under the plasma concentration time curve from time zero to time t [AUC(t)] 1746.97 ng · h/mL, CV 31.6%) and in the fed state (mean C(max) 120.99 ng/mL, CV 15.0%; mean AUC(t) 1712.20 ng · h/mL, CV 26.7%). No statistically significant between-treatment differences were observed for any of the pharmacokinetic parameters under study. The fed : fasting ratios of the geometric least squares means with corresponding 90% confidence intervals for C(max) and AUC(t) were within the range of 80-125%. CONCLUSION: High-fat, high-calorie food intake does not affect the kinetics of doxylamine in healthy subjects. The drug was safe and well tolerated by the subjects in this study.